Merck Celebrates Topping-Out Ceremony for New Membrane Production Plant
PR85990
DARMSTADT, Germany, Oct. 8, 2020 /PRNewswire=KYODO JBN/ --
- Membrane manufacturing facility for aseptic filters will help meet customer
demand in the growing biopharmaceutical market
- Investment of more than (EUR) 140 million creates approximately 55 new jobs
- Construction expected to be completed in 2022
Merck, a leading science and technology company, today celebrated the
topping-out ceremony for its new membrane production plant in Darmstadt,
Germany. With the new facility, the company plans to expand manufacturing of
Millipore Express(R) (
) membranes, which are critical components in Millipore Express(R) filters and
help ensure the sterility of biological drug products. The project with a
volume of more than (EUR) 140 million is part of the (EUR) 1 billion investment
in its global headquarters until 2025 that the company announced last year.
Photo -
https://mma.prnewswire.com/media/1308804/Merck_membrane_manufacturing_image.jpg
"As a science and technology company, we want to pave the way for new therapies
and contribute to improving the lives of patients around the world. With this
strategically important production facility for our Life Science business
sector, we are investing in a future technology, enabling additional growth and
creating new jobs at our company's global headquarters," said Stefan Oschmann,
chairman of the Executive Board and CEO of Merck.
Chris Ross, interim CEO of the Life Science business, added: "As a
world-leading life science tools and solutions provider, we play a pivotal role
in the growing biopharmaceutical membrane market. This investment increases our
membrane manufacturing capacity and allows for more supply chain
diversification. It also demonstrates our commitment to advancing the
production of new therapies and our support for bringing important drugs to
market."
The new membrane production plant is expected to create approximately 55 new
jobs. Construction began in March this year and is expected to be completed in
2022, followed by production process validation and commercialization. The new,
four-story membrane plant will house immersion membrane casting equipment,
quality control laboratories and offices.
Millipore Express(R) (
) membranes from Merck will be manufactured at the new facility in Darmstadt,
then processed into filters for pharmaceutical production at the company's
existing device Center of Excellence in Jaffrey, New Hampshire, USA.
With more than 50 years of experience in sterile filtration, Merck is an
industry leader, providing the most comprehensive portfolio of products,
services and testing for biopharmaceutical manufacturing. Millipore Express(R)
membranes and Durapore(R) membranes are produced today at the Center of
Excellence for membrane manufacturing in Cork, Ireland. The Merck Life Science
Center in Cork remains a critical manufacturing facility within the company's
global network.
All Merck news releases are distributed by email at the same time they become
available on the Merck website. Please go to www.merckgroup.com/subscribe to
register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare,
life science and performance materials. Around 56,000 employees work to make a
positive difference to millions of people's lives every day by creating more
joyful and sustainable ways to live. From advancing gene editing technologies
and discovering unique ways to treat the most challenging diseases to enabling
the intelligence of devices -- the company is everywhere. In 2019, Merck
generated sales of (EUR)16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to
Merck's technological and scientific advances. This is how Merck has thrived
since its founding in 1668. The founding family remains the majority owner of
the publicly listed company. Merck holds the global rights to the Merck name
and brand. The only exceptions are the United States and Canada, where the
business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma
in life science and EMD Performance Materials.
SOURCE: Merck
CONTACT: andreas.cezanne@merckgroup.com, Phone: +49 6151 72 45946
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
